Statistically significant (p < 0.001) decreases in Tregs (CD3 + CD4 + CD25 + CD127low/−) were observed at 6, 168, and 336 h (Fig. 1b), as predicted based on data from a phase I study of single-agent mogamulizumab in patients with CCR4− lung and esophageal cancers [25]. The gene discussed is CD4; the disease is esophageal cancer.